Eli Lilly struck a research collaboration with METiS TechBio to redesign lipid nanoparticles for tissue-specific delivery, using AI to guide lipid selection and formulation. The deal structure allows Lilly to pay up to $1.1 billion depending on milestones, signaling high confidence in the delivery platform rather than only a single therapeutic application. The partnership targets a core limitation in nucleic-acid and gene-expression modalities: getting drugs into the right tissue at the right dose while minimizing off-target exposure. If successful, AI-accelerated LNP design could shorten formulation cycles and expand the addressable indications for RNA-based pipelines. For the drug-delivery market, the agreement also reinforces the shift toward compute-intensive discovery stacks that pair algorithmic formulation design with experimental iteration and eventual regulatory-grade scale-up.